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OBJECTIVES: The PROVE IT-TIMI 22 trial demonstrated clin-
ical beneﬁt of intensive lipid lowering (atorvastatin 80 mg) vs.
moderate lipid lowering (pravastatin 40 mg) in patients with
acute coronary syndrome (ACS). Prior US analysis found lower
net costs for intensive Rx. The objective of this analysis was to
evaluate cost-effectiveness of intensive vs. moderate statin
therapy in ACS patients in the UK, Germany and Canada where
generic pravastatin is available and hospitalization costs lower
than in the US. METHODS: Hospitalization and length of treat-
ment were obtained from PROVE-IT case report forms. Hospi-
talizations were classiﬁed by relevant DRG system and
multiplied by associated hospitalization costs in the UK,
Germany and Canada. Drug costs were obtained from each
country’s public or tariff prices. RESULTS: Compared with mod-
erate pravastatin therapy, intensive atorvastatin therapy was
associated with fewer hospitalizations (1301 vs. 1444; 0.62/pt
vs. 0.70/pt). Total costs (hospital + drug) per patient of intensive
vs. moderate therapy were ≤3184 vs. ≤3236 (UK), €5242 vs.
€5515 (Germany) and CA$7386 vs. CA$8087 (Canada), with
savings per patient of ≤56, €284 and CA$701 respectively over
the 2-year study period. Thus, increased drug acquisition costs
were more than offset by reduced hospitalization costs in all
three countries. Sensitivity analysis on treatment pattern varia-
tions, events and costs will be conducted. If the PROVE-IT
results are generalizable to all ACS patients, the savings from
intensive vs. moderate statin therapy per two years of treatment
would be £5.6 million, €28.4 million and CA$70.1 million for
every 100,000 ACS patients in the UK, Germany and Canada,
respectively. CONCLUSIONS: As observed in PROVE-IT, inten-
sive atorvastatin therapy reduced clinical events and costs com-
pared to moderate pravastatin therapy among ACS patients in
the UK, Germany and Canada and thus is clinically beneﬁcial at
a lower overall cost among PROVE-IT ACS patients, allowing
allocation of resources to other therapy options.
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OBJECTIVE: Often cost-effectiveness analyses must be under-
taken before a price for the product has been set. This study eval-
uated the expected cost-effectiveness of rimonabant, the ﬁrst
selective CB-1 receptor blocker, for treatment of patients with
dyslipidemia in the UK under various price assumptions.
METHODS: A Markov model (SHAPE) was developed using
data from clinical trials, published risk equations and UK patient
proﬁles from the Health Outcomes Data Repository Database
(HODaR) registry. Patients transition from At Risk or Diabetes
to CVD based on UKPDS 68 or Framingham Heart study 
equations, or to death based on UK life-tables, and to diabetes 
(San Antonio Heart study) and subsequent CVD events
(Saskatchewan equations). UK costs for acute resource use upon
transition as well as longer term routine management are accrued
in 2005 GBP. Age-dependent utilities are calculated and tariffs
for all events and states are applied. Rimonabant effects on car-
diometabolic risk factors were taken from the RIO Lipids trial.
Ten year and lifetime horizons were examined; all outcomes were
discounted at 3.5%/yr. Extensive probabilistic sensitivity analy-
ses were carried out. RESULTS: Over ten years, >13% of
patients are expected to suffer a cardiovascular event with a loss
of more than 1045 QALYs and a cost above £600,000 per 1000
patients. Adding rimonabant to diet & exercise for only one year
is estimated to gain >100 QALYs over a lifetime. Preliminary
cost-effectiveness ratios remained acceptable (less then
≤20,000/QALY) under a wide range of assumptions and when
testing hypothetical prices as high as ≤8 per day. CONCLU-
SIONS: Based on the reductions in total to HDL cholesterol
ratio, weight and other risk factors seen in RIO Lipids trial,
rimonabant should substantially reduce cardiovascular risk in
obese or overweight patients with dyslipidemia and result in an
acceptable cost-effectiveness ratio.
METHODS & CONCEPTS I
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OBJECTIVES: 1) To quantify and characterize the cost-utility
analyses (CUAs) published in the scientiﬁc literature through
2003; and 2) to examine methodological practices used in these
CUAs. This paper builds upon our previous analyses that eval-
uated CUAs from 1976 through 2001. METHODS: We system-
atically searched Medline and the Health Economic Evaluations
Database (HEED) for original CUAs written in English and pub-
lished during 2002–2003 to update a comprehensive registry of
CUAs (www.tufts-nemc.org/cearegistry). Two trained readers
independently extracted data on the characteristics and method-
ology of each study. We compared recently published
(2002–2003) with previously published (1976–2001) data.
RESULTS: Our previous search identiﬁed 533 original CUAs
published during 1976–2001; a ﬁnding of 262 studies published
during 2002–2003 increased the sample by almost 50%. In the
1976–2001 and 2002–2003 data, most studies were based in the
US (61%, 53%) and written by academics (90%, 92%). Studies
examined treatment (63%, 62%) more than primary (14%,
16%) and secondary (22%, 21%) prevention. The most frequent
condition studied was cardiovascular disease (21%, 18%). Per-
centage of funding by the pharmaceutical and device industry
did not change substantially (19%, 23%). Studies improved with
time across the two datasets: disclosing funding source (65% vs.
71%), stating year of currency (76% vs. 82%), reporting incre-
mental ratios (59% vs. 79%), and using probabilistic sensitivity
analyses (9% vs. 28%). CONCLUSIONS: The publication of
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CUAs has accelerated in recent years. Use of recommended
methods has increased, although a sizeable number of analyses
still do not adhere to best practice. Continued monitoring of
these trends is crucial to enhancing the quality of the ﬁeld.
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OBJECTIVES: Response sift (RS) and recall bias (RB) cause
problems in patient-reported outcomes (PRO). RS refers to the
change of meaning in health-related quality of life (HRQoL) in
pretest-posttest design. RB is the result of variation in the recall
of earlier HRQoL states, satisfaction and symptoms. To present
a new composite HRQoL tool for integrating contemporaneous
items with recall/response items. The innovative aim of the
generic 15Ds tool is the adjustment of RB/RS. METHODS: The
widely utilized 15D tool yields both 15-dimensional health pro-
ﬁles and an overall HRQoL index. The 15D was promoted by
the WHO health deﬁnition and the additive valuation of multi-
attribute utility theory (MAU) to produce quality-adjusted life
years (QALY). The 15Ds was innovated by the literature and
pragmatic experience with the 15D. RESULTS: The 15Ds con-
tains 15 contemporary dimensions with ﬁve states (i.e. the con-
ventional 15D), 15 recall/response dimensions with six states for
transitions, and three validation dimensions. The recall/response
dimensions adjust subjects’ contemporary states for RB/RS. The
validation dimensions contain a comparison of the subject’s
general health state to the health of a same-age population (5
states), RB/RS comparison for health transitions (6 states), and
comparison for the level of healing (illness conceptualization, 5
states). A preliminary analysis revealed that patients have more
sensitivity for changes measured as the recall/response items than
for changes in the contemporary items over time. The 15Ds gives
slightly better outcomes in the index changes and offers higher
discrimination for the changes of HRQoL when compared with
the conventional 15D. CONCLUSIONS: The 15Ds can produce
15-dimensional contemporary health proﬁles, 15-dimensional
recall/response health proﬁles, overall HRQoL index for both
15Ds and 15D, and approximations for the validation of tran-
sitions, health and illness. The 15Ds is recommended for recall
(e.g. acute conditions when no baseline HRQoL is obtainable)
and RB/RS adjustment.
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OBJECTIVES: In previous work, we explored through com-
puter-aided simulated clinical trials how heterogeneity of base-
line risk can lead to heterogeneity of treatment-effect under a
variety of assumptions. We now explore how heterogeneity of
competing risks affect treatment-effect heterogeneity under a
variety of assumptions. METHODS: Using simulated clinical
trials in which the intervention has a constant effect on disease-
speciﬁc risk (odds ratio = 0.7) but no effect on competing risk
and in which outcomes in individuals are determined by varying
2 parameters: (1) the overall risk of the outcome of interest and
(2) the ratio between the competing risk and the disease-speciﬁc
(i.e. treatment-responsive) risk. RESULTS: Under conditions in
the simulations, the odds ratio of the treatment-effect on the
overall outcome is highly dependent on the ratio of the compet-
ing and disease-speciﬁc risk, decreasing as this ratio increases.
Although the absolute treatment-effect increases with increasing
overall risk, the odds ratio for the treatment decreases as the
overall risk increases (holding constant the ratio between disease-
speciﬁc and competing risk). When disease-speciﬁc outcomes are
measured, a similar relationship between treatment-effect and
overall risk is observed, although the decrease in the odds ratio
with increasing risk is greatly attenuated. Detecting signiﬁcant
treatment-effect heterogeneity (on the odds ratio scale) based on
competing risk is likely to occur only when competing risk is
very high or when patients can be sub-grouped by variables
which distinguish between disease-speciﬁc and competing risk.
CONCLUSION: The ratio of competing risk to disease-speciﬁc
risk in a population can have an important impact on the mea-
sured treatment effect, even when disease-speciﬁc outcomes are
measured. Detection of competing-risk-based treatment-effect
heterogeneity may depend on the identiﬁcation of risk factors
that differentiate disease-speciﬁc from competing risk. Simula-
tions can be useful to anticipate the magnitude of these effects
when planning a clinical trial.
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OBJECTIVES: The recommendation of the US Panel to incor-
porate productivity costs in terms of health effects (QALYs) in a
cost-effectiveness analysis aroused quite some debate. A crucial
yet under-explored question in this debate is whether people
include effects of ill-health on income in health state valuations
(HSV). The same holds for the actual inclusion in HSV of the
effects of ill-health on leisure. This study aims to test whether
respondents to health-state valuations using TTO questions
include the effects of ill-health on income and leisure when the
measure is silent on both. Moreover, it tests the consequences of
explicit instructions to either include or exclude the income-
effects in HSV. METHODS: Three questionnaires were devel-
oped and administered among the general public. Respondents
were asked to value three distinct EQ-5D health-states using
TTO. In version 1 respondents did not receive instructions on
including or excluding income-effects in their valuations, but
inclusion was assessed afterwards. In versions 2 and 3 respon-
dents were instructed upfront to incorporate income-effects or
to assume that income would not change. They were further-
more asked whether they included the effects of ill-health on
leisure-time in their HSV. RESULTS: In version 1 64% of the
respondents spontaneously included income-effects in their HSV.
In version 2 and 3 88% included leisure-time. There were no dif-
ferences in the valuations of respondents including or excluding
income-effects, also in case of explicit instruction. Inclusion of
leisure-time resulted in a signiﬁcantly lower TTO-value in only
one of the three health-states. CONCLUSIONS: Respondents do
not consistently include income- and leisure-effects in their val-
uations. Including income-effects (spontaneously or instructed)
does not seem to affect TTO-valuations and may therefore best
be placed on the cost-side of the cost-effectiveness ratio. Leisure-
